KLRA

Kailera Therapeutics, Inc.

Healthcare · Biotechnology

$121.51 sample

-1.89 (-1.53%) 1D

Market cap

$621.7B

Price as of

2026-10-04

Latest filing

8-K · 2026-09-04

Alerts

8

Price$121.51 +15.85% 3M daily closessample

123.40104.89

2026-07-072026-07-292026-08-202026-09-102026-10-02

purchase / approvalsale / rejectionfiling / neutral

Latest events

Filings, trades, FDA; newest first

Sep 29INSInsider sell: EVP, Operations
Sep 18INSInsider buy: EVP, Operations
Sep 15INSInsider sell: Chief Executive Officer
Sep 04SECForm 144 filed
Aug 27INSInsider sell: Chief Executive Officer
Aug 19INSInsider sell: General Counsel
Aug 12SEC10-Q filed
Aug 07INSInsider buy: EVP, Operations

Sign up to see the real KLRA record →

Company facts

SEC EDGAR registration

Name: Kailera Therapeutics, Inc.
Sector: Healthcare
Industry: Biotechnology
Smart-money score: -55sample, -100 to +100
Reporting currency: USD

Who is positioning in KLRA

sample

Insiders: 24 insider transactions over 90 days, net selling, $696.3M
Congress: 1 members traded over 90 days
Institutions · 13F: 21 funds hold $10.6B
Activists · 13D/G: No 13D/13G activist filings on record

How are the fundamentals trending?

sample, by period end

Revenue$32.5B +16.2% y/y

Q4 2024Q3 2026

Inventory$19.9B +13.4% y/y

Q4 2024Q3 2026

Accounts receivable$15.2B +15.1% y/y

Q4 2024Q3 2026

Total debt$41.3B +13.3% y/y

Q4 2024Q3 2026

Peers

sample

Sample peer A: $483.9B +6.1% 3M
Sample peer B: $511.1B +13.9% 3M
Sample peer C: $416.6B -11.1% 3M
Sample peer D: $404.1B +16.0% 3M
Sample peer E: $346.1B +6.1% 3M